trending Market Intelligence /marketintelligence/en/news-insights/trending/kgeu1gbgqkfngmnsslg9oq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Aptose to buy China rights to CrystalGenomics' blood cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aptose to buy China rights to CrystalGenomics' blood cancer drug

Aptose Biosciences Inc. signed a licensing deal to develop and commercialize South Korea-based CrystalGenomics Inc.'s blood cancer drug in China, including Hong Kong and Macau.

CG-806 is an investigational treatment for patients with acute myeloid leukemia, B-cell malignancies and other hematologic malignancies. Acute myeloid leukemia is a type of cancer characterized by the bone marrow's production of abnormal myeloblasts, red blood cells or platelets.

Under the agreement, Aptose will give CrystalGenomics US$3 million in an up-front payment. CrystalGenomics will also receive development, regulatory and commercial-based milestone payments, along with single-digit royalties on product sales in the Chinese market, for a total deal value of US$125 million.

The new deal expands Aptose's exclusive license to develop and commercialize CG-806 globally, except Korea.